Citi Pharma Ltd (CITI)

Currency in PKR
93.99
-0.61(-0.64%)
Delayed Data·

CITI Financial Summary

Key Ratios

P/E Ratio23.66
Price/Book3.53
Debt / Equity52.84%
Return on Equity15.04%
Dividend Yield3.58%
EBITDA1.34B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2016
30/06
2017
30/06
2018
30/06
2019
30/06
2020
30/06
2021
30/06
2022
30/06
2023
30/06
2024
30/06
* In Millions of PKR (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 3.64%
Dividend Yield
3.44%
Industry Median 2.43%
Annualised payout
3.25
Paid annually
5-Years Growth
-
Growth Streak

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 0.00

Earnings

Latest Release
May 28, 2025
EPS / Forecast
0.96 / --
Revenue / Forecast
3.34B / --
EPS Revisions
Last 90 days

FAQ

What were Citi Pharma's earnings for the latest quarter?

The Citi Pharma EPS (TTM) is 3.64. Citi Pharma reported sales of 3,341.11, net income of 220.38, and EPS of 0.96 for the latest quarter.

What was Citi Pharma's net income for the latest quarter?

Citi Pharma's net income for the latest quarter was 220.38.

How did Citi Pharma's performance compare year-over-year in the latest quarter?

The company's revenue moved from 3,534.43 in the previous quarter to 3,341.11 in the latest quarter, and net income moved from 256.98 to 220.38 compared to the previous quarter.

What is Citi Pharma's net profit margin on a TTM basis?

Citi Pharma's trailing twelve months (TTM) net profit margin is 6.72%.

How does Citi Pharma's debt to equity ratio compare to industry standards?

Citi Pharma's total debt-to-equity ratio is 52.84%.

What is Citi Pharma's return on investment on a TTM basis?

Citi Pharma's trailing twelve months (TTM) return on investment (ROI) is 15.04%.

Did Citi Pharma gain or lose cash last quarter?

In the latest quarter, Citi Pharma's net change in cash was 57.41 million.

What were Citi Pharma's total assets and liabilities in the latest quarter?

As of the latest quarter, Citi Pharma reported total assets of 13,602.10 million and total liabilities of 7,778.26 million.

How has Citi Pharma's total revenue grown this year?

Citi Pharma's total revenue was 3,534.43 in the previous quarter and 3,341.11 in the latest quarter.

What is Citi Pharma's gross margin on a TTM basis?

Citi Pharma's trailing twelve months (TTM) gross margin is 13.10%.

What was Citi Pharma's revenue per share for the latest quarter?

Citi Pharma's revenue per share for the latest quarter was 478.36.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.